Silverback is preparing an IPO to promote the development of cancer and hepatitis B ADC drugs

Silverback's pipeline is based on its ImmunoTAC platform, which binds antibodies to small molecules that regulate the immune system, unlike ADCs that routinely carry cytotoxic drugs.
this method can target paths that were previously untouchable due to the side effects of small molecules.
Silverback's fastest-growing project is SBT6050, targeting TLR8 in HER2-positive solid tumors.
antibodies ensure that small molecule drugs are delivered to cancer cells that express HER2, such as certain breast, stomach, and non-small cell lung cancers, while TLR8 agonists activate myelin cells to attack tumors and "reprogram" tumor microenvirons. Dr. Valerie Odegard, president and chief scientific officer of
Silverback, said in an interview that the SBT6050 is an improvement on TLR8 astrists because existing TLR8 astrists must be systematically given and have side effects, limiting the amount of medicine patients can take.
SBT6050 is currently undergoing Phase 1/1b clinical trials for patients with solid tumors expressed in advanced or metastasis HER2.
trials have observed single-drug pharmacological activity in the first dose queue and an interim data update for phase 1 dose climbing queues is expected to be published in the second half of 2021.
Silverback plans to use the proceeds of the IPO primarily for the Phase 1 clinical trial, including the expansion of specific tumor species and the Phase 1b study in association with PD-1 inhibitors.
, the funds will also push another project, SBT6290, to submit an IND application and enter Phase 1 Clinical in the fourth quarter of 2021, according to the filing.
SBT6290 also activates TLR8, but targets Nectin4, which is expressed in lung cancers that include certain bladder, triple negative, head and neck, and non-small cell lung cancers.
addition, the proceeds from the IPO will help the third project for TLR8, SBT8230, but it is not used in the field of oncology.
ADC combines a small molecule drug with a single anti-target ASGR1 to treat chronic hepatitis B infection.
Silverback hopes to submit an IND application for SBT8230 in the second half of 2022.
addition to this, Silverback is also working on the development of topical therapies that regulate important pathages in other tumors and fibrosis adaptations.
Reference 1. Silverback tees up $100M IPO to pushADCs for cancer, Hep B.2. Silverback Therapeutics website 3. Silverback Therapeutics, Inc. IPOInvestment Prospectus S-1。